KDELR3 and cancer: The high expression of KDELR3 was associated with reduced drug sensitivity of cancer cells to 53 drugs (Valrubicin, Cyclophosphamide, Teniposide, Palbociclib, Daunorubicin, Oxaliplatin et al.)and with increased drug sensitivity of cancer cells to eight drugs (Irofulven, Zoledronate, Simvastatin, Abiraterone, IPI-145 et al.).